WASHINGTON (CN) - Drugmakers that Teva Pharmaceuticals has accused of patent infringement must present their invalidity defense to the Supreme Court, the justices said Monday.
Teva, along with Yeda Research and Development and other affiliates, brought suit against seven companies including Sandoz and Mylan, after they tried to market generic versions of Copaxone, a Teva drug used in treating multiple sclerosis.
A federal judge in Manhattan ultimately found that the defendants had infringed various claims of nine Teva patents-in-suit, but the Federal Circuit gave the drugmakers some relief last year in finding a group of claims invalid for indefiniteness.
The Supreme Court granted Teva a writ of certiorari Monday without issuing any comment on the case, as is its custom.
Teva is represented by William Jay of the Washington firm Goodwin Procter. Sandoz is represented by Morrison & Foerster attorney Deanne Maynard, and Mylan is represented by Eric Miller with Perkins Coie in Seattle.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
Additional Reads
-
Alaska, Hawaiian Airlines April 17, 2024 -
-
Contributor-Test-Post-2024-04-12 April 12, 2024 -
